[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiomyopathy-dilated\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiomyopathy-dilated":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,54,78,108,133,163,191],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":38,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100558055","national-network-for-cardiovascular-genomics-advancing-cardiovascular-healthcare-for-hereditary-diseases-in-brazils-unified-health-system-through-a-multicenter-registry-100558055",false,"NCT06546137","National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry","RENOMICA-Hcor","Inclusion Criteria:\n\n* Clinical diagnosis of a hereditary cardiovascular disease according to current clinical guidelines\n* Agree to receive genetic counseling\n* Sign informed consent form\n* Provide the information required in the case report form\n\nExclusion Criteria:\n\n* Signature absent from informed consent form\n* Inadequate buccal swab (sample may be collected twice)","ALL",{"count":18,"type":19},1211,"ESTIMATED","6 Months","OBSERVATIONAL","The goal of this observational study is to develop a registry of Brazilian patients with hereditary cardiovascular diseases, combining clinical and genomic data. The main questions it aims to answer are:\n\nWhich genes are most commonly affected? What is the frequency of these genetic alterations in our population? Participants will be interviewed in routine medical care visits and their DNA will be sequenced.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37],"Cardiomyopathy, Hypertrophic","Cardiomyopathy, Dilated","Cardiomyopathy Restrictive","Arrhythmogenic Right Ventricular Dysplasia","Non-Compaction Cardiomyopathy","Familial Hypercholesterolemia","Marfan Syndrome","Ehlers-Danlos Syndrome, Vascular Type","Loeys-Dietz Syndrome","Long QT Syndrome","Short Qt Syndrome","Brugada Syndrome","Catecholaminergic Polymorphic Ventricular Tachycardia","Sudden Cardiac Death",[39,40],"hereditary cardiovascular diseases","whole genome sequencing","RECRUITING","2026-05-04",{"date":44,"type":45},"2026-05-08","ACTUAL",{"date":47,"type":45},"2025-04-30",{"date":49,"type":19},"2026-08-31",{"name":51,"class":52},"Hospital do Coracao","OTHER",27,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100634222","effect-of-sildenafil-on-left-ventricular-function-in-pediatric-with-primary-dilated-cardiomyopathy-100634222","NCT07536880","Effect of Sildenafil on Left Ventricular Function in Pediatric With Primary Dilated Cardiomyopathy","Effect of Sildenafil on Left Ventricular Function in Pediatric Patients With Primary Dilated Cardiomyopathy Prospective Cohort Study","AssiutU","Inclusion Criteria:- Children from 1-18 year's age, diagnosed primary dilated cardiomyopathy by echocardiography and are admitted at Pediatric Cardiology unit or attend Pediatric Cardiology outpatient clinic in Assiut University children hospital.\n\n* Patient on anti-failure therapy consistent with pediatric heart failure guidelines.\n\nExclusion Criteria:. Patients less than 1 year old\n\n\\- Patients with impaired left ventricular systolic function due to other causes like: i. Congenital heart diseases (anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA), severe coarctation of aorta, critical aortic stenosis, metabolic disorders as mitochondrial dysfunction or storage diseases.\n\nii. Acquired heart diseases as myocarditis, Kawasaki, or arrhythmias\n\n* Post-Operative left ventricular dysfunction\n* Known hypersensitivity or contraindications to sildenafil as hypotension (\\\u003C90\u002F50 mmHg), or severe hepatic\u002Frenal impairment or optic neuropathy.","1 Year","18 Years",{"count":65,"type":19},70,"Dilated cardiomyopathy (DCM) is a clinical diagnosis characterized by left ventricular or biventricular dilation and impaired contraction that is not explained by abnormal loading conditions.(1) Both inherited predisposition and environmental factors play an important part in the natural history of disease.(1) Cardiomyopathies are group of heart diseases that influence cardiac muscles directly and are not related to hypertension, congenital, valvular and pericardial diseases. The most common type of cardiomyopathy is dilated cardiomyopathy (DCM).(2) Definitions of DCM provided by two major professional organizations (American Heart Association (AHA) and European Society of Cardiology (ESC)) Both organizations agreed that DCM could be clinically defined by the presence of left ventricular dilation and contractile dysfunction in the absence of abnormal loading conditions and severe coronary artery disease.(3) Dilated cardiomyopathy usually manifests as chronic systolic heart failure, which is detected by echocardiography as impaired left ventricle fraction shortening less than 28%, with left ventricular end diastolic dimension Z-score\\>2 ,leading to arrhythmias and sudden death.(4,5) idiopathic dilated cardiomyopathy (DCM) is characterized by dilatation and impaired contraction of the left ventricle or both ventricles, in the absence of underlying causes such as CAD, valve disease, congenital heart disease, or pericardial disease. Most patients present with symptoms of heart failure or arrhythmias, or even sudden cardiac death. An extensive family history (pedigree covering three or four generations), in combination with cardiological screening of first-degree relatives, results in a diagnosis of a familial form of DCM in up to 35% of cases.(11) In a multisite study in the USA and Canada, DCM was the most common form of cardiomyopathy among children (individuals of \\\u003C18 years of age):66% had idiopathic DCM, whereas of those with DCM due to known causes, 46% had myocarditis and 26% had neuromuscular disease. The annual incidence of DCM in children ranges from 0.18 to 0.73 per 100,000 person-years.(1) Oral PDE5 inhibitors, which primarily include sildenafil, vardenafil ,and tadalafil. Owing to its vasodilation effect and its impact on the endothelial function of blood vessels in the body, it is possible to use them to treat cardiovascular disorders such as pulmonary arterial hypertension and dilated cardiomyopathy. The use of PDE5 inhibitors in HF patients is backed by various theoretical evidence and clinical trials have begun to investigate their potential as an adjunct in the pharmacological management of HF.(6) PDE5 inhibition is an intriguing pharmacological strategy that enhances in vivo NO signaling by increasing the cyclic guanosine monophosphate (cGMP) availability. A number of theoretical backgrounds support the use of PDE5 inhibitors in HF, and several recent clinical studies have tested its clinical viability as a potential adjunct in the pharmacological management of HF.(7) In chronic heart failure improvement in exercise ventilation and aerobic efficiency with sildenafil is sustained and is significantly related with an endothelium-mediated attenuation of exercising muscle over signaling. Chronic sildenafil seems to be a remedy based on CHF pathophysiology and devoid of remarkable adverse effects.(8) Sildenafil is a specific inhibitor of type 5 phosphodiesterase (PDE5) that increases nitric oxide availability and nitric oxide-mediated vasodilation in CHF patients). Interest has therefore been focused on the potential of sildenafil to be beneficial in CHF. In acute studies, sildenafil increased myocardial contractility ,blunted adrenergic stimulation ,reduced left ventricular afterload), and improved lung diffusion capacity ,pulmonary hemodynamics at rest) and on exertion ,and exercise ventilation efficiency and aerobic performance.(8)",[25],"NOT_YET_RECRUITING","2026-04-12",{"date":71,"type":45},"2026-04-17",{"date":73,"type":19},"2026-05-10",{"date":75,"type":19},"2027-05-30",{"name":77,"class":52},"Assiut University",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":16,"minAge":63,"maxAge":4,"enrollmentInfo":87,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100633517","cardiac-magnetic-resonance-clinical-prediction-model-dilated-cardiomyopathy-100633517","NCT07527715","Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated Cardiomyopathy","Study on Risk Early Warning of Clinical Prediction Model Based on Multi-Parameter Stress Perfusion Cardiac Magnetic Resonance in Adverse Prognosis of Dilated Cardiomyopathy","MPS-CMR-DCM","Inclusion Criteria\n\n1.An elevated left ventricular end-diastolic volume indexed to body surface area and reduced LVEF, compared with published age- and gender-specific reference values Exclusion Criteria\n\n1. significant coronary artery disease (CAD), defined as a stenosis of ˃50% in a major coronary artery\n2. infiltrative disease\n3. valvular cardiomyopathy\n4. arrhythmogenic cardiomyopathy\n5. congenital heart disease",true,{"count":88,"type":19},2000,"Dilated cardiomyopathy (DCM) is a common and serious heart disease characterized by left ventricular enlargement and impaired pumping function, with adverse prognosis (including heart failure, arrhythmia, heart-related hospitalization, and death) being a major concern for patients. Currently, a critical gap exists in accurately predicting which DCM patients are at high risk of these severe outcomes, limiting targeted clinical care.\n\nThis observational, non-invasive study aims to develop and validate a clinical prediction model for early risk warning of adverse prognosis in DCM patients. The model integrates multi-parameter stress perfusion cardiac magnetic resonance (MP stress perfusion CMR)-a safe, high-resolution imaging technique that assesses cardiac structure, function, blood perfusion, and tissue damage under mild stress-and standard clinical data (e.g., age, gender, blood pressure, and routine heart test results).\n\nThe model will be trained and tested using follow-up data from hundreds of DCM patients, with the analysis identifying patterns in CMR and clinical data associated with adverse outcomes. Once validated for accuracy, the model will provide doctors with personalized risk scores to prioritize care for high-risk patients (e.g., early intervention, close monitoring) and avoid over-treatment for lower-risk individuals.\n\nBeyond clinical application, the study will enhance understanding of DCM progression, laying the groundwork for improved diagnostic tools, more effective treatments, and better strategies to prevent DCM-related complications, ultimately improving patient quality of life and reducing mortality.",[25,91,92,93,94,95,96],"Prognosis","Magnetic Resonance Imaging, Cardiac","Death, Sudden, Cardiac","Heart Failure","Risk Assessment","Stress Perfusion","2026-04-09",{"date":99,"type":45},"2026-04-14",{"date":101,"type":45},"2021-12-01",{"date":103,"type":19},"2038-12-01",{"name":105,"class":106},"Shandong Provincial Hospital","OTHER_GOV",1,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":63,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100630712","rhythm-and-myocardial-function-relationship-evaluation-in-heart-diseases-100630712","NCT07491237","RHYthm and Myocardial Function Relationship Evaluation in Heart Diseases","RHYME-HD","Inclusion Criteria:\n\n* Only patients aged \\> 18 years with a history of arrhythmia warranting non-pharmacological treatment according to the guidelines will be selected.\n* Collection of informed consent for the prospective cohort.\n* For the retrospective cohort, the Promoter has carried out a Data Protection Impact Assessment (DPIA), which ascertained the adequacy of the technical and organisational measures adopted to ensure the protection of the fundamental rights and freedoms of data subjects, in accordance with Article 89 of Regulation (EU) 2016\u002F679 and the guidelines of the Data Protection Authority. Data processing will be limited to the purposes of the study and conducted in accordance with the principles of minimisation, pseudonymisation and security, in compliance with the guarantees defined by the Data Protection Authority.\n\nExclusion Criteria:\n\n* Patients who, upon initial assessment at our centre, do not present arrhythmias that would indicate non-pharmacological treatment.\n* Patients for whom it is not possible to obtain adequate medical history and\u002For follow-up through medical examination or telephone consultation.\n* Refusal to give informed consent to participate in the study.",{"count":116,"type":19},253,"Arrhythmias are widespread among the global population. Although they can occur in healthy hearts, they are often the manifestation of a hereditary or acquired heart muscle disease, and may be the cause or, more often than not, the consequence.\n\nIn recent decades, with advances in medical knowledge and technology, non-pharmacological therapies for arrhythmias have become increasingly popular. These fall into two broad categories: therapies aimed at electrostimulation and those aimed at ablation of arrhythmias.\n\nThe selection of patients eligible for these procedures is essential for the effectiveness of the therapy, the reduction of complications and the optimisation of resources.\n\nNot all patients, even those selected according to guidelines, respond equally to the chosen therapy. Other patients, due to their clinical\u002FECG characteristics, do not have clear indications and remain in a borderline area where the class of evidence and\u002For recommendation of the guidelines is less stringent. Still others develop recurrences or complications during follow-up that require further intervention.\n\nIn this context, it is essential in the study of these patients not only to use standard instrumental examinations, such as echocardiograms, Holter ECGs and stress tests (simple and cardiopulmonary), but also and above all to use advanced imaging methods (STE, 3D echo, MRI, CT, PET-CT) and remote monitoring tools that integrate diagnostic algorithms managed by artificial intelligence.\n\nIn light of these considerations, our project consists of conducting an observational study that includes all patients with arrhythmias who are candidates for electrostimulation and\u002For ablation procedures at the Arrhythmology Unit and\u002For followed up at the Arrhythmology Clinic of our Polyclinic, in order to assess the clinical and\u002For imaging characteristics associated with a worse prognosis in this population, in terms of response to therapy and development of complications. Our main aim is to identify, within the above-mentioned population, the subgroups of responder patients versus non-responder patients, i.e. those with a worse prognosis , who deserve greater attention and more frequent follow-up.",[119,25,120,121,122,94,123],"Arrhythmia","Systolic Dysfunction","Atrial Fibrillation","Ventricular Arrythmia","Cardiomyopathies","2026-03-18",{"date":126,"type":45},"2026-03-24",{"date":128,"type":19},"2026-04-15",{"date":130,"type":19},"2031-12-31",{"name":132,"class":52},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":63,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":144,"phases":145,"briefSummary":147,"conditions":148,"keywords":149,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":107},"100463990","phase-3-early-treatment-with-candesartan-vs-placebo-in-genetic-carriers-of-dilated-cardiomyopathy-early-gene-trial-100463990","NCT05321875","Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)","Early Treatment With Candesartan vs Placebo in Asymptomatic Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)\"","EARLY-GENE","Inclusion Criteria:\n\n* Age: 18-64 (both included), both sexes\n* Carrier of a pathogenic or likely pathogenic DCM genetic variant1 according to modified American College of Medical Genetics (ACMG) criteria.\n* Baseline LVEF ≥ 50% measured by MRI1 and evaluated by the eligibility study committee. Carriers with myocardial fibrosis, detected by late gadolinium enhancement in magnetic resonance imaging, are valid.\n* Baseline creatinine ≤1.3 mg\u002FdL, potassium ≤ 5.3 mEq\u002FL and an estimated Glomerular Filtration Rate (eGFR)≥ 60 ml\u002Fmin\u002F1.73 m2 calculated by CKD-EPI formula.\n* Able to understand and accept the study constraints and to provide informed consent.\n\nExclusion Criteria:\n\n* Hypotension (systolic arterial pressure \\\u003C100 mmHg (measured following a standardized methodology).\n* Prior ventricular dysfunction (LVEF ≤ 50% at any time prior to study inclusion)\n* Candidates who are expected or highly likely to receive an implantable cardioverter defibrillator (ICD) in the following 12 months after inclusion in the trial\n* Preexisting hypertension requiring pharmacological treatment.\n* Uncontrolled arterial hypertension (i.e., repeatedly systolic arterial pressure \\> 140 mmHg).\n* Carriers of TTN-truncating variants (TTNtv) who are \\\u003C 35 years old.\n* Known clinically significant coronary artery disease (e.g., ≥70% stenosis in any epicardial artery or ≥50% of left main coronary artery), valvular disease (≥ moderate in severity) or ventricular arrhythmias.\n* Ongoing treatment with ACEI, ARB, ARNI or MRA.\n* Prior intolerance to ACE inhibitors or ARB.\n* Presence of any contraindications to receive candesartan treatment, including severe liver failure and\u002For cholestasis\n* Known bilateral renal artery stenosis.\n* Uncontrolled concomitant severe disease (e.g., with expected survival inferior to the duration of the study follow-up)\n* Participation in any other clinical trial using an investigational medicinal product or device in the 30 days previous to the inclusion in the study.\n* Current pregnancy, breastfeeding or women of childbearing age who are not willing to practice an adequate birth control during the entire duration of the study (a negative pregnancy test result must be confirmed at the time of enrolment)\\*.\n* Drug or alcohol abuse (current).\n* Inability to comply with study procedures and treatments.\n* Carriers of MRI incompatible internal devices (ICD, pacemakers, aneurysm clips, etc.), with known intolerance to MRI studies or presenting any contraindications to perform cardiac MRI studies.\n* Any circumstances that in the investigator's opinion compromise the participant's ability to participate in the clinical trial.","64 Years",{"count":143,"type":19},320,"INTERVENTIONAL",[146],"PHASE3","Prospective, multicenter, randomized, placebo-controlled, double-blind clinical trial to evaluate safety and efficacy of candesartan in the prevention of the development of Dilated Cardiomyopathy (DCM) in genetic carriers of a DCM-causing variant without disease expression (asymptomatic)",[25],[150,151,152,153],"Dilated Cardiomyopathy","Genetic Mutation Carrier","Randomized Clinical Trial","Genetic Dilated Cardiomyopathy","2024-11-06",{"date":156,"type":45},"2024-11-07",{"date":158,"type":45},"2022-06-02",{"date":160,"type":19},"2026-06-02",{"name":162,"class":52},"Cristina Avendaño Solá",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":63,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":144,"phases":174,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":107},"100523119","therapy-to-maintain-remission-in-dilated-cardiomyopathy-100523119","NCT06091475","Therapy to Maintain Remission in Dilated Cardiomyopathy","A Randomised Trial Examining Therapy to Maintain Remission in Dilated Cardiomyopathy","TRED-HF2","Inclusion Criteria:\n\n1. a diagnosis of dilated cardiomyopathy,\n2. previous left ventricular ejection fraction (LVEF) \\\u003C40% (on echocardiography or cardiovascular magnetic resonance \\[CMR\\]),\n3. current LVEF \\>50% with normal left ventricular end-diastolic volume (LVEDV),\n4. plasma NT-pro-BNP\\\u003C250ng\u002FL,\n5. New York Heart Association (NYHA) class I,\n6. sinus rhythm,\n7. taking a beta-blocker and an angiotensin converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB) or sacubitril-valsartan, along with either a mineralocorticoid receptor antagonist (MRA) and\u002For sodium glucose co-transporter 2 inhibitor (SGLT2i).\n\nExclusion Criteria:\n\n1. Atrial fibrillation,\n2. prior sustained ventricular tachycardia or fibrillation,\n3. a known likely pathogenic or pathogenic variant in LMNA\u002FDSP\u002FFLNC\u002FRBM20,\n4. sudden cardiac or heart failure death in a first degree relative \\\u003C50 years,\n5. contraindication to CMR,\n6. estimated glomerular filtration rate (eGFR) \\\u003C60mls\u002Fmin,\n7. planned pregnancy,8) active myocardial inflammation,\n\n9\\) diabetes mellitus managed with an SGLT2i, 10) urinary albumin-to-creatine ratio of 200-5000 (mg:g) and eGFR\\\u003C 75mls\u002Fmin.","85 Years",{"count":173,"type":19},50,[175],"NA","One third of patients diagnosed with heart failure demonstrate left ventricular reverse remodelling and recovery of cardiac function following a period of medical therapy. The TRED-HF trial investigated the impact of therapy withdrawal in this cohort and found that 40% of patients relapsed within 6 months of stopping treatment. In this follow-on study, the investigators will investigate the safety of therapy withdrawal of sodium cotransporter 2 inhibitors (SGLT2i) and mineralocorticord receptor anatagonists (MRAs) in patients with a previous diagnosis of heart failure and recovered cardiac function, in a randomised controlled trial to assess whether this maintains remission in this population.",[94,25,123,178],"Heart Diseases",[180,181],"Cardiomyopathy","heart failure","2024-09-03",{"date":184,"type":45},"2024-09-19",{"date":186,"type":45},"2023-12-02",{"date":188,"type":19},"2026-09-15",{"name":190,"class":52},"Imperial College London",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":63,"maxAge":198,"enrollmentInfo":199,"targetDuration":201,"studyType":21,"phases":4,"briefSummary":202,"conditions":203,"keywords":204,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":107},"100243300","registry-of-cell-therapy-in-non-ischemic-dilated-cardiomyopathy-100243300","NCT02445534","Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy","RECORD","Inclusion Criteria:\n\n* Patient inclusion criteria consisted of the following: age 18-65 years old, diagnosis of DCM according to the European Society of Cardiology position statement (9), optimal medical management for at least 6 months, left ventricular ejection fraction (LVEF) \\\u003C40%, and New York Heart Association functional Class III on stable medical therapy for at least 3 months before referral.\n\nExclusion Criteria:\n\n* Patients with acute multi-organ failure or a history of hematologic neoplasms were not included.","65 Years",{"count":200,"type":19},250,"5 Years","Although several studies have demonstrated beneficial effects of stem cell therapy in patients with non-ischemic dilated cardiomyopathy, the long term benefits and predictors of response to therapy remain undefined. The aim of this registry is to pool long-term clinical data in patients with non-ischemic dilated cardiomyopathy undergoing autologous cell therapy in an attempt to better define predictors of response to such treatment.",[25],[205],"Cell Therapy","2024-07-01",{"date":208,"type":45},"2024-07-03",{"date":210,"type":4},"2005-01",{"date":212,"type":19},"2027-05",{"name":214,"class":52},"University Medical Centre Ljubljana"]